



Specifications

Rapid Exchange

Shaft / Balloon material:
Nylon (3 fold)

Coating:
Hydrophilic - Distal shaft
Silicon - Proximal shaft

Diameter Guidewire:
0.014"

Nominal pressure:
8 ATM

RBP:
16 ATM - 2.5/3.0 mm
14 ATM - 3.5 mm



Code number	Stent diameter	Stent length	Profile	Max. shaft size	Min. shaft size	Entry profile	Usable length
DE-RA2508SM	2.5 mm	8	0.042" / 1.05 mm	2.5 F / 0.84 mm	2.0 F / 0.67 mm	0.017" / 0.43 mm	145 cm
DE-RA2514SM		14					
DE-RA2518SM		18					
DE-RA2524SM		24					
DE-RA2528SM		28					
DE-RA3008SM	3.0 mm	8	0.044" / 1.11 mm				
DE-RA3014SM		14					
DE-RA3018SM		18					
DE-RA3024SM		24					
DE-RA3028SM		28					
DE-RA3508LM	3.5 mm	8	0.045" / 1.13 mm				
DE-RA3514LM		14					
DE-RA3518LM		18					
DE-RA3524LM		24					
DE-RA3528LM		28					

TERUMO CORPORATION

44-1,2-chome, Hatagaya,
Shibuya-ku,
Tokyo 151-0072 - Japan
Tel 81 3 3374 8111
Fax 81 3 3374 8196

TERUMO EUROPE NV

Researchpark Zone 2 - Haasrode
Interleuvenlaan 40
B-3001 Leuven
Belgium
Tel 32 16 38 12 11
Fax 32 16 40 02 49

TERUMO EUROPE

INTERVENTIONAL SYSTEMS
Parc Ariane - Bât. Jupiter
1 rue Hélène Boucher
78284 Guyancourt Cedex
France
Tel 33 1 39 30 95 75
Fax 33 1 39 30 95 70

TERUMO DEUTSCHLAND GmbH

Hauptstrasse 87
D-65760 Eschborn
Germany
Tel 49 6196 8023 0
Fax 49 6196 8023 200

LABORATOIRES TERUMO

FRANCE S.A.
Parc Ariane - Bât. Uranus
1 rue Hélène Boucher
78284 Guyancourt Cedex
France
Tel 33 1 30 96 13 00
Fax 33 1 30 43 60 85

TERUMO ITALIA SRL

Via Simone Martini, 143-145
00142 Roma RM
Italy
Tel 39 06 51 96 14 20
Fax 39 06 50 30 407

TERUMO EUROPE

ESPAÑA SL
Av da. Juan Carlos 1ª Planta 7ª
Edificio Torre La Garena
28806 Alcalá de Henares
Madrid Spain
Tel 34 902 10 12 98
Fax 34 902 10 13 58

TERUMO UK Ltd

Tamesis
The Causeway
Egham
Surrey TW20 9AW
United Kingdom
Tel 44 178 447 6200
Fax 44 178 447 6201

TERUMO EUROPE NV

BENELUX SALES DIVISION
Researchpark Zone 2 - Haasrode
Interleuvenlaan 40
B-3001 Leuven
Belgium
Tel 32 16 39 25 80 (Belgium)
Fax 32 16 39 25 99 (Belgium)
Tel 0800 0220 396 (NL)
Fax 0800 0220 414 (NL)

TERUMO SWEDEN AB

Nya Varvet, Byggnad 90
Sven Källfelts Gata 18
SE-426 71 Västra Frölunda
Sweden
Tel 46 31 748 58 80
Fax 46 31 748 58 90


MOSCOW REPRESENTATIVE

OFFICE OF TERUMO EUROPE NV
4, Ivana Franko St,
Moscow, Russia, 121108
Tel 7 495 234-3303
Fax 7 495 234-3303

TERUMO DEUTSCHLAND GmbH

Zweigniederlassung Wettingen/ Schweiz
Bahnhofstrasse 88
CH 5430 Wettingen/ AG
Tel +41 56 419 10 10
Fax +41 56 419 10 11

www.terumo-europe.com
© Registered Trademark
Manufactured by Terumo Europe
© TERUMO EUROPE



ISS2GB-0405MID18101081E



Nobori

Drug Eluting Stent


Reliable, forever.



Biolimus A9, a Rapamycine Derivative

Biolimus A9, an anti-proliferative and anti-inflammatory compound

- Highly lipophilic.
- Optimal uptake by target tissue.
- Effective prevention of smooth muscle cell proliferation.
- Precise release kinetics with an initial burst and sustained elution through polymer degradation.
- Exceptionally low systemic level.



Superior Stent Design

Ideal platform for drug delivery

- Excellent flexibility offered by the quadrature-link design.
- Convenient side branch access.
- Optimal scaffolding.
- Uniform drug distribution.



Biodegradable Polymer PLA on Abluminal Surface

Poly(lactic Acid) (PLA) with long history of medical applications

- A naturally occurring polymer.
- High precision exclusively abluminal coating.
- Fully degrades within several months leaving no residual drug on the stent.
- Final degradation into carbon dioxide and water.



No remaining polymer is observed



Stent explanted after 12 months from rabbit iliac artery showing smooth strut surface and absence of D, L-PLA.
Source: Terumo Corporation, Study at CVPath – Virmani R.

Excellent Deliverability

Nobori™ mounted on innovative Nagare™ delivery system

- Proprietary hydrophilic M-coating to maximize deliverability.
- Terumo's recognized catheter quality and reliability.
- Smooth and precise stent positioning to the target lesion.
- Low crossing profile for access to tortuous anatomy.



Rapid Functional Re-Endothelialization

Unique design: No drug on luminal surface

- Allows attachment of endothelial progenitor cells.
- Less inhibition of endothelial growth.
- Functional endothelial coverage for long-term safety.

Bare stent Nobori




Complete re-endothelialization at 28 days
Source: Virmani R. et al.

Exceptional Clinical Results

NOBORI 1, Phase 1, 9 months results (1)

Target Lesion Revascularization	0.0%
Angiographic restenosis in-stent	0.0%
Angiographic restenosis in-segment	0.0%
Stent thrombosis	0.0%
Target Vessel Failure	5.9%
Late Loss in-stent	0.15 mm
Late Loss in-segment	0.09 mm



Top Grade NOBORI Clinical Program

Trial	Description
NOBORI 1 – Phase 1 (1)	Randomized controlled trial vs. Taxus Express Primary endpoint: In-stent late loss at 9 months
NOBORI 1 – Phase 2 (2)	Randomized controlled trial vs. Taxus Liberté Primary endpoint: In-stent late loss at 9 months
NOBORI PK (5)	Pharmacokinetics study Primary endpoint: Biolimus A9 concentration at 28 and 90 days
NOBORI CORE (4)	Comparative trial vs. Cypher stent Primary endpoint: In-stent late loss at 9 months
NOBORI CORE (3) Endothelial Function	Comparative trial vs. Cypher Primary endpoint: endothelial functionality at 9 months
NOBORI Japan	Randomized controlled trial vs. Cypher Primary endpoint: Target vessel failure at 9 months
NOBORI 2	Multicentre real life registry with pre-specified high risk subsets Primary endpoint: MACE at 12 months

(1) Chevalier B. et al. Randomized comparison of Nobori, Biolimus A9-eluting coronary stent with Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The NOBORI 1 trial. *EuroIntervention* 2007 2:426-4.

(2) Chevalier B. et al. NOBORI 1, 9 months results phase 2. 2007 www.tctmd.com

(3) Hamilos M. et al. Differential Effects of Drug Eluting Stents on Local Endothelium Dependent Coronary Vasomotion. *J Am Coll Cardiol* (in press).

(4) Ostojic M. et al. First clinical comparison of Nobori – Biolimus A9 eluting stent with Cypher™ – sirolimus eluting stent; NOBORI CORE 9 months angiographic and one year clinical outcomes. *EuroIntervention* (accepted).

(5) Ostojic M. et al. NOBORI PK. 2006 - www.pcr.com